Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
Anti-CD20
Augment
IMiD
Relevance
Safety
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
02
2020
revised:
12
03
2020
accepted:
14
03
2020
pubmed:
19
4
2020
medline:
8
9
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Frontline treatment for patients with indolent non-Hodgkin lymphoma often includes immunochemotherapy. Although the disease of most patients responds to initial treatment, relapse is common. Recent results from the phase 3 Augment trial showed that combining rituximab with the immunomodulatory drug lenalidomide (R
Identifiants
pubmed: 32303486
pii: S2152-2650(20)30142-7
doi: 10.1016/j.clml.2020.03.009
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
563-571Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.